Skip to search formSkip to main contentSkip to account menu

agalsidase beta

Known as: agalsidase beta [Chemical/Ingredient] 
National Institutes of Health

Related topics

Related topics

7 relations

Broader (2)

ALPHA-D-GALACTOSIDASE ENZYMEIsoenzymes
Alpha-glucosidaseDrug AllergyFabry Diseaseanalogs & derivatives

Narrower (1)

Fabrazyme

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Improvement of Fabry Disease-Related Gastrointestinal Symptoms in a Significant Proportion of Female Patients Treated with Agalsidase Beta: Data from the Fabry Registry.
Fabry disease, an X-linked inherited lysosomal storage disorder, is caused by mutations in the gene encoding α-galactosidase, GLA… 
Review
2017
Review
2017
Switch to agalsidase alfa after shortage of agalsidase beta in Fabry disease: a systematic review and meta-analysis of the literature
Background:In 2009, the agalsidase beta shortage resulted in switching to agalsidase alfa treatment for many Fabry disease… 
Highly Cited
2012
Highly Cited
2012
Renal outcomes of agalsidase beta treatment for Fabry disease: role of proteinuria and timing of treatment initiation
Background. The purpose of this study was to identify determinants of renal disease progression in adults with Fabry disease… 
Review
2012
Review
2012
Agalsidase alfa: a review of its use in the management of Fabry disease.
  • G. Keating
  • BioDrugs : clinical immunotherapeutics…
  • 2012
  • Corpus ID: 40445936
The enzyme replacement therapy agalsidase alfa (Replagal®) has an amino acid sequence identical to that of native α-galactosidase… 
Review
2012
Review
2012
Agalsidase Alfa
The enzyme replacement therapy agalsidase alfa (Replagal®) has an amino acid sequence identical to that of native α-galactosidase… 
2011
2011
Role of cardiac MRI in evaluating patients with Anderson-Fabry disease: assessing cardiac effects of long-term enzyme replacement therapy
PurposeAnderson-Fabry disease is a multisystemic disorder of lipid metabolism secondary to X-chromosome alterations and is… 
Review
2010
Review
2010
Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry Registry
Disclosure: The Fabry Registry is sponsored by Genzyme Corporation. U.F.-R., K.S., R.J.H., M.B., A.M., and A.P.B. serve on the… 
Review
2007
Review
2007
Agalsidase-Beta Therapy for Advanced Fabry Disease
Context Fabry disease is an X-linked storage disorder characterized by deficient lysosomal enzyme activity and excessive… 
Highly Cited
2005
Highly Cited
2005
Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy.
Review
2004
Review
2004
Clinical benefit in Fabry patients given enzyme replacement therapy—A case series
Summary: Fabry disease is a rare lysosomal storage disorder resulting from deficient activity of α-galactosidase A and subsequent… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License